FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2590759126> ?p ?o ?g. }

• W2590759126 endingPage "296" @default.
• W2590759126 startingPage "296" @default.
• W2590759126 abstract "296 Background: Protracted outpatient oral chemotherapy regimens have created new challenges for monitoring patients for toxicity. Unlike IV chemotherapy which guarantees clinician access to the patient before proceeding with therapy, oral agents can continue to be taken despite missed follow-up visits and lab draws. After observing patients return from unrecognized lapses in monitoring with severe myelosuppression, we sought to retrospectively measure risks and to prospectively test a software-based monitoring system designed to flag and notify team members of missed lab monitoring. Methods: We evaluated 117 patients who had received a standard 42-day continuous course of oral temozolomide as therapy for newly diagnosed primary malignant brain tumors to assess monitoring compliance, as well as adverse events. Standard practice is to obtain a weekly CBC with differential and platelets during the 6 weeks of concurrent chemoradiation. Grade 3 or higher hematologic events were observed in 9 (7.7%) patients. Gaps in monitoring were defined as no testing for 10 days or more, and were classified as minor (10-12 days) and major (13-27 days). Results: 34 (29.1%) patients had one or more gaps during treatment; 19 (16.2%) had majors and 18 (15.4%) had minors. 2 of the patients with gaps in coverage exhibited grade 3 or 4 myelosuppression upon their return to monitoring. We have currently monitored 36 patients prospectively with prototype software designed to email staff whenever a patient was not monitored for 7 days or had scheduled visits too far in the future. The software uses data downloaded from the electronic medical record (12,889 labs, [908 pertinent], 441 visits) and was effective in finding patients that missed labs or did not get properly scheduled visits. Five such mistakes were detected and 4 were corrected based on the system flag. Problems encountered were mainly false positives associated with entry of chemotherapy stop dates. Conclusions: Monitoring failures pose risks to patients receiving oral chemotherapy and traditional medical information systems make detection of missing data difficult. Systems such as ours are simple to build and could be integrated with most EMR systems." @default.
• W2590759126 created "2017-03-03" @default.
• W2590759126 creator A5006007842 @default.
• W2590759126 creator A5008595217 @default.
• W2590759126 creator A5010216039 @default.
• W2590759126 creator A5010839484 @default.
• W2590759126 creator A5054729243 @default.
• W2590759126 creator A5075387275 @default.
• W2590759126 date "2012-12-01" @default.
• W2590759126 modified "2023-09-26" @default.
• W2590759126 title "An automated system for insuring monitoring of myelosuppression in patients receiving self-administered oral chemotherapy." @default.
• W2590759126 doi "https://doi.org/10.1200/jco.2012.30.34_suppl.296" @default.
• W2590759126 hasPublicationYear "2012" @default.
• W2590759126 type Work @default.
• W2590759126 sameAs 2590759126 @default.
• W2590759126 citedByCount "0" @default.
• W2590759126 crossrefType "journal-article" @default.
• W2590759126 hasAuthorship W2590759126A5006007842 @default.
• W2590759126 hasAuthorship W2590759126A5008595217 @default.
• W2590759126 hasAuthorship W2590759126A5010216039 @default.
• W2590759126 hasAuthorship W2590759126A5010839484 @default.
• W2590759126 hasAuthorship W2590759126A5054729243 @default.
• W2590759126 hasAuthorship W2590759126A5075387275 @default.
• W2590759126 hasConcept C126322002 @default.
• W2590759126 hasConcept C177713679 @default.
• W2590759126 hasConcept C194828623 @default.
• W2590759126 hasConcept C197934379 @default.
• W2590759126 hasConcept C2776694085 @default.
• W2590759126 hasConcept C2777389519 @default.
• W2590759126 hasConcept C71924100 @default.
• W2590759126 hasConceptScore W2590759126C126322002 @default.
• W2590759126 hasConceptScore W2590759126C177713679 @default.
• W2590759126 hasConceptScore W2590759126C194828623 @default.
• W2590759126 hasConceptScore W2590759126C197934379 @default.
• W2590759126 hasConceptScore W2590759126C2776694085 @default.
• W2590759126 hasConceptScore W2590759126C2777389519 @default.
• W2590759126 hasConceptScore W2590759126C71924100 @default.
• W2590759126 hasIssue "34_suppl" @default.
• W2590759126 hasLocation W25907591261 @default.
• W2590759126 hasOpenAccess W2590759126 @default.
• W2590759126 hasPrimaryLocation W25907591261 @default.
• W2590759126 hasRelatedWork W1970674393 @default.
• W2590759126 hasRelatedWork W2031376430 @default.
• W2590759126 hasRelatedWork W2073885660 @default.
• W2590759126 hasRelatedWork W2088407372 @default.
• W2590759126 hasRelatedWork W2090078020 @default.
• W2590759126 hasRelatedWork W2371666691 @default.
• W2590759126 hasRelatedWork W2378355431 @default.
• W2590759126 hasRelatedWork W2547383728 @default.
• W2590759126 hasRelatedWork W2607482886 @default.
• W2590759126 hasRelatedWork W59994307 @default.
• W2590759126 hasVolume "30" @default.
• W2590759126 isParatext "false" @default.
• W2590759126 isRetracted "false" @default.
• W2590759126 magId "2590759126" @default.
• W2590759126 workType "article" @default.